Evaluating response‐adaptive randomization procedures for recurrent events and terminal event data using a composite endpoint.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1167, doi. 10.1002/pst.2253
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2022 AND VI 21 AND IP 6
Results: 20
1
2
Comments on "Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab phase 2 bioequivalence study".
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1366, doi. 10.1002/pst.2255
- By:
- Publication type:
- Article
3
Win ratio approach for analyzing composite time‐to‐event endpoint with opposite treatment effects in its components.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1342, doi. 10.1002/pst.2248
- By:
- Publication type:
- Article
4
Improving early phase oncology clinical trial design: A case study.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1370, doi. 10.1002/pst.2252
- By:
- Publication type:
- Article
5
A semi‐mechanistic dose‐finding design in oncology using pharmacokinetic/pharmacodynamic modeling.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1149, doi. 10.1002/pst.2249
- By:
- Publication type:
- Article
6
Response to the letter to the editor regarding our article 'statistical methodology for highly variable compounds: A novel design approach for the ofatumumab phase 2 bioequivalence study' https://doi.org/10.1002/pst.2233.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1368, doi. 10.1002/pst.2254
- By:
- Publication type:
- Article
7
CUSUMIN: A cumulative sum interval design for cancer phase I dose finding studies.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1324, doi. 10.1002/pst.2247
- By:
- Publication type:
- Article
8
Confirmatory efficacy testing for individual dose–placebo comparisons using serial gatekeeping procedure in dose‐finding trials with multiple comparison procedures–modeling.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1309, doi. 10.1002/pst.2246
- By:
- Publication type:
- Article
9
Weighted log‐rank test to compare two survival functions in the presence of dependent censoring.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1281, doi. 10.1002/pst.2245
- By:
- Publication type:
- Article
10
Estimators for handling COVID‐19‐related intercurrent events with a hypothetical strategy.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1258, doi. 10.1002/pst.2244
- By:
- Publication type:
- Article
11
A MCP‐Mod approach to designing and analyzing survival trials with potential non‐proportional hazards.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1294, doi. 10.1002/pst.2241
- By:
- Publication type:
- Article
12
Standard and reference‐based conditional mean imputation.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1246, doi. 10.1002/pst.2234
- By:
- Publication type:
- Article
13
Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence study.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1357, doi. 10.1002/pst.2233
- By:
- Publication type:
- Article
14
Two‐stage subgroup‐specific time‐to‐event (2S‐Sub‐TITE): An adaptive two‐stage time‐to‐toxicity design for subgroup‐specific dose finding in phase I oncology trials.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1138, doi. 10.1002/pst.2231
- By:
- Publication type:
- Article
15
The utilities and pitfalls of stratified analysis in challenging situations.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1114, doi. 10.1002/pst.2232
- By:
- Publication type:
- Article
16
Empirical likelihood inference for area under the receiver operating characteristic curve using ranked set samples.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1219, doi. 10.1002/pst.2230
- By:
- Publication type:
- Article
17
Optimal unplanned design modification in adaptive two‐stage trials.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1121, doi. 10.1002/pst.2228
- By:
- Publication type:
- Article
18
A Bayesian latent class model for predicting gestational age in health administrative data.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1199, doi. 10.1002/pst.2225
- By:
- Publication type:
- Article
19
Doubly‐robust methods for differences in restricted mean lifetimes using pseudo‐observations.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1185, doi. 10.1002/pst.2223
- By:
- Publication type:
- Article
20
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 6, p. 1111, doi. 10.1002/pst.2138
- Publication type:
- Article